Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab for type 2 inflammation-related dermatoses
ChiCTR2200058210Phase 4Recruiting
- Sponsor
- Huashan Hospital
- Start
- Apr 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label trial of dupilumab in Bullous Pemphigoid (BP), prurigo nodularis (PN) and chronic idiopathic urticaria (CIU) (2 cohorts), sponsored by Huashan Hospital. Primary endpoint: Time to disease control. Started Apr 2022; status: recruiting.
02
Drugs
03
Conditions
Bullous Pemphigoid (BP)prurigo nodularis (PN)chronic idiopathic urticaria (CIU)
Beyond the preview
Go deeper on ChiCTR2200058210.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058210.